Quidel Corp (NASDAQ: QDEL) reported Q2 EPS of ($0.11), $0.14 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $39.1 million versus the consensus estimate of $37.98 million.

"In the second quarter, which has typically been our lowest revenue period for the year, double-digit sales growth over the prior year quarter was once again achieved," said Douglas Bryant, president and CEO of Quidel Corporation. "Influenza product revenues grew 21%, driven by a number of factors including the persistence of Influenza B into early April in a handful of states, low distributor inventories at the end of March, and market share gains. Non-flu product sales grew 8%, led by a number of key non-flu franchises. Bone Health and Complement marker revenue was up 57%, total molecular sales were up 63%, Graves' Disease was up 8%, and non-molecular Group A Strep revenue was up 13%."

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.